(0.14%) 5 529.50 points
(0.18%) 39 540 points
(0.09%) 19 945 points
(0.26%) $81.75
(-1.42%) $2.56
(0.00%) $2 339.50
(-0.08%) $29.54
(-1.68%) $997.10
(-0.31%) $0.930
(-0.31%) $10.64
(-0.16%) $0.789
(1.93%) $87.38
0.72% HKD 19.54
Live Chart Being Loaded With Signals
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N...
Stats | |
---|---|
Объем за сегодня | 360 785 |
Средний объем | 1.30M |
Рыночная капитализация | 6.82B |
EPS | HKD-0.690 ( Q1 | 2024-03-31 ) |
Дата следующего отчета о доходах | ( HKD-0.400 ) 2024-08-27 |
Last Dividend | HKD0.937 ( 2022-07-13 ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
-2.97 (Sector) 0 (Industry) 0 |
ATR14 | HKD0.0280 (0.14%) |
Объем Корреляция
Cansino Biologics Inc Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Cansino Biologics Inc Корреляция - Валюта/Сырье
Cansino Biologics Inc Финансовые показатели
Annual | 2023 |
Выручка: | HKD345.18M |
Валовая прибыль: | HKD-876.02M (-253.78 %) |
EPS: | HKD-6.01 |
FY | 2023 |
Выручка: | HKD345.18M |
Валовая прибыль: | HKD-876.02M (-253.78 %) |
EPS: | HKD-6.01 |
FY | 2022 |
Выручка: | HKD1.03B |
Валовая прибыль: | HKD-186.61M (-18.10 %) |
EPS: | HKD-3.91 |
FY | 2021 |
Выручка: | HKD4.30B |
Валовая прибыль: | HKD3.00B (69.85 %) |
EPS: | HKD7.74 |
Financial Reports:
No articles found.
Cansino Biologics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.937 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.937 | 2022-07-13 |
Last Dividend | HKD0.937 | 2022-07-13 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.937 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
13 Jul 2022 | HKD0.937 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
1691.HK | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
0086.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
6886.HK | Ex Dividend Junior | 2023-07-12 | Annually | 0 | 0.00% | |
1126.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2607.HK | Ex Dividend Junior | 2023-07-18 | Annually | 0 | 0.00% | |
0709.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
1929.HK | Ex Dividend Knight | 2023-07-12 | Semi-Annually | 0 | 0.00% | |
0267.HK | Ex Dividend Junior | 2023-09-22 | Semi-Annually | 0 | 0.00% | |
1346.HK | Ex Dividend Knight | 2023-09-12 | Annually | 0 | 0.00% | |
0002.HK | Ex Dividend Knight | 2023-09-04 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -4.22 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.177 | 1.200 | -5.89 | -7.06 | [0 - 0.3] |
returnOnEquityTTM | -0.274 | 1.500 | -4.16 | -6.24 | [0.1 - 1] |
payoutRatioTTM | -0.0448 | -1.000 | -0.448 | 0.448 | [0 - 1] |
currentRatioTTM | 2.39 | 0.800 | 3.05 | 2.44 | [1 - 3] |
quickRatioTTM | 2.19 | 0.800 | 1.810 | 1.448 | [0.8 - 2.5] |
cashRatioTTM | 1.228 | 1.500 | 4.29 | 6.43 | [0.2 - 2] |
debtRatioTTM | 0.247 | -1.500 | 5.88 | -8.82 | [0 - 0.6] |
interestCoverageTTM | -22.80 | 1.000 | -9.56 | -9.56 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.66 | 2.00 | -0.885 | -1.770 | [0 - 30] |
freeCashFlowPerShareTTM | -4.80 | 2.00 | -2.40 | -4.80 | [0 - 20] |
debtEquityRatioTTM | 0.415 | -1.500 | 8.34 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -2.35 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -4.45 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.309 | 1.000 | -2.83 | -2.83 | [0.2 - 2] |
assetTurnoverTTM | 0.0419 | 0.800 | -3.05 | -2.44 | [0.5 - 2] |
Total Score | -3.85 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.96 | 1.000 | -0.400 | 0 | [1 - 100] |
returnOnEquityTTM | -0.274 | 2.50 | -2.67 | -6.24 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -4.80 | 2.00 | -1.601 | -4.80 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.66 | 2.00 | -0.885 | -1.770 | [0 - 30] |
payoutRatioTTM | -0.0448 | 1.500 | -0.448 | 0.448 | [0 - 1] |
pegRatioTTM | -0.222 | 1.500 | -4.81 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.824 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.99 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cansino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа